Respiratorius AB (publ)

NGM:RESP Stock Report

Market Cap: SEK 24.5m

Respiratorius Valuation

Is RESP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RESP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RESP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RESP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RESP?

Key metric: As RESP is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for RESP. This is calculated by dividing RESP's market cap by their current book value.
What is RESP's PB Ratio?
PB Ratio0.8x
BookSEK 32.18m
Market CapSEK 24.47m

Price to Book Ratio vs Peers

How does RESP's PB Ratio compare to its peers?

The above table shows the PB ratio for RESP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.8x
SPAGO Spago Nanomedical
1.6x78.0%SEK 64.8m
DEX Dextech Medical
2.6xn/aSEK 75.4m
ABERA Abera Bioscience
7.3xn/aSEK 62.2m
COEGIN Coegin Pharma
3.7x16.4%SEK 81.1m
RESP Respiratorius
0.8xn/aSEK 24.5m

Price-To-Book vs Peers: RESP is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (3.8x).

Price to Book Ratio vs Industry

How does RESP's PB Ratio compare vs other companies in the SE Biotechs Industry?

8 CompaniesPrice / BookEstimated GrowthMarket Cap
EXPRS2 ExpreS2ion Biotech Holding
0.6x-11.9%US$3.60m
SCOL Scandion Oncology
0.4x69.7%US$1.49m
DIABIO Diagonal Bio
0.5xn/aUS$1.12m
CYXO Cyxone
0.4xn/aUS$1.07m
RESP 0.8xIndustry Avg. 2.5xNo. of Companies10PB02.44.87.29.612+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: RESP is good value based on its Price-To-Book Ratio (0.8x) compared to the Swedish Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is RESP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RESP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RESP's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

PMD Device Solutions

SEK 35.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.36

7D

-2.9%

1Y

n/a

Camurus

SEK 32.6b

A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.

CAMX

SEK 553.50

7D

0.6%

1Y

22.2%

Corline Biomedical

SEK 137.5m

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.

CLBIO

SEK 6.40

7D

-7.5%

1Y

-48.2%